⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38658426 | 1.00 | — | — | |
| SCHEMBL22434499 | 0.97 | CDC7 (0.35) | — | |
| SCHEMBL21955672 | 0.89 | CREBBP (0.40) | — | |
| SCHEMBL21955671 | 0.85 | CDC7 (0.31) | — | |
| SCHEMBL14028662 | 0.84 | CRBN (0.39) | — | |
| SCHEMBL23008640 | 0.83 | KDM4E (0.33) | — | |
| SCHEMBL22753505 | 0.83 | BRD4 (0.45) | — | |
| SCHEMBL22753516 | 0.82 | — | — | |
| SCHEMBL12148832 | 0.79 | — | — | |
| SCHEMBL11032332 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101799-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230150976-A1 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | UNIVERSITY OF ROCHESTER (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220024919-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-01-27 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | ROGER WILLIAMS HOSPITAL (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | ROGER WILLIAMS HOSPITAL (US) | 2008-10-09 | — | — | US | disclosed |